Norton Rose Fulbright (NRF) was the legal adviser of an Australian-founded medicinal cannabis company on its IPO and listing on the ASX.
Althea Group raised $19.65m in its fully subscribed IPO, which NRF said had strong participation from institutional and professional investors from around the world. It was also supported by Toronto-listed Aphria, which is one of Canadas largest medicinal cannabis companies and a cornerstone investor in Althea even before the IPO.
NRF fielded a cross-practice team led by corporate partner Chris Mitchell. The team advised on all aspects of its IPO and admission to the official list of ASX, including pre-IPO fundraising initiatives, prospectus preparation, due diligence…
Read the full article at: https://www.australasianlawyer.com.au/news/nrf-helps-medicinal-cannabis-company-on-asx-float-255881.aspx